Biogen BIIB recently announced that the FDA has granted Breakthrough Therapy designation to Salanersen, an investigational ...
Six weeks of resistance training with a new wearable device more than doubled spinal muscular atrophy patients' leg strength, ...
Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene ...
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary muscle movement, according to the Muscular Dystrophy Association (MDA). It can ...
A local family has a personal stake in the donations that pour into St. Jude Children’s Research Hospital. Every month, the ...
Salanersen, which is designed for once-yearly dosing, is a potential successor to Biogen's blockbuster SMA drug Spinraza, which generated worldwide sales of nearly $1.55 billion last year and requires ...
Forbes contributors publish independent expert analyses and insights. Spinal muscular atrophy affects the nerves that control muscle movement, leading to progressive weakening. As a result, infants ...
Spinal muscular atrophy (SMA) and spina bifida are distinct conditions that affect the nerves that allow for voluntary motor control. Share on Pinterest press coverage photography/Getty Images SMA is ...
After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug ...
If you or your child has spinal muscular atrophy (SMA), a team of medical professionals can help you manage your symptoms. A great care team will also help lessen complications. That will greatly ...
Spinal muscular atrophy (SMA) is a genetic, progressive neuromuscular disorder. SMA affects muscle-controlling nerve cells, called motor neurons, in the spinal cord. The condition leads to muscle ...
Evrysdi, also known as risdiplam, is an oral medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families. It leads to ...